# OnCo record asparaginase (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/asparaginase/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "asparaginase" ;
  schema:name "Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)"@en ;
  schema:description "An enzyme that starves leukaemia cells of an amino acid they cannot make; a mainstay of childhood ALL therapy for 50 years, with new versions solving allergy and supply problems."@en ;
  schema:url <https://onco.cc/drugs/asparaginase/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Asparaginase> ;
  owl:sameAs <http://www.wikidata.org/entity/Q105296036> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Rylaze> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Enzyme therapy" ;
  schema:alternateName "Oncaspar / Asparlas / Rylaze / Erwinaze" ;
  onco:approval "US 1994: ALL (pegaspargase, hypersensitivity to native); first line 2006", "US 2018: ALL in patients 1 month-21 years (calaspargase pegol)", "US 2021: ALL/LBL with hypersensitivity to E. coli asparaginase (Rylaze)", "EU 2016: Oncaspar centralised 2016; Erwinase and native asparaginases national" ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:companies <https://onco.cc/companies/servier/>, <https://onco.cc/companies/jazz/> .